Ligufalimab targets CD47, enhancing macrophage-mediated cancer cell destruction, and avoids red blood cell clumping, improving safety and efficacy. Early trials show ligufalimab, combined with Vidaza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results